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Abstract  
In high-dose intake of phenytoin, which is used frequently to treatepilepsy, nystagmus, diplopia, nausea-vomiting, lethargy, confusion, seizure, and 
coma can be observed. In recent studies on phenytoin intoxication, in which seizure and coma were observed in drug levels greater than 50 
ug/mL. The serum phenytoin level of apatient, who consumed approximately 100 pcs of 100 mg phenytoin tablets in an effort to commit suicide, 
and who had no pathological finding in her neurologic examination, was 124 ug/mL. High drug level and the absence of toxic effect (or the 
absence of toxic effect correlated with the drug level) indicates that cytochrome P450 is functioning, but there can be a mutation in the MDR1 
gene. In our case study, we report on phenytoin intoxication in a patient having a high level of phenytoin but no symptoms correlated with serum 
drug level, as supported by the findings in the literature. 
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Phenytoin has been used as an anticonvulsant since the late 1930s. 
It blocks voltage-dependent sodium channels, limiting the 
propagation of seizure discharges. This response is mediated by a 
use-dependent and voltage-dependent decrease in the rate of 
recovery of voltage-activated sodium channels from inactivation [1]. 
The multi-drug resistance (MDR) gene family is a sub-family of the 
ATP-binding-cassette (ABC) transporter super family. While MDR1 is 
the gene coding the glycoproteins that are responsible for drug 
transport, MDR2/3 are the genes coding the glycoproteins that do 
not play a role in drug transport [2]. Among the MDR1 gene 
products, phosphorylation of P-glycoprotein (PGP) regulates the 
transport of drugs out of cells [3]. PGP-expressing cells increase the 
concentration gradient of a drug [4]. This paper reports on 
phenytoin intoxication in a 36-year-old female patient having a 
serum phenytoin level of 124 ug/mL and no symptoms correlated 
with serum drug level, as supported by findings from the literature.  
  
  
Patient and observation 
 
A 36-year-old female patient, who had a history of bipolar disorder, 
was brought to our emergency department by her relatives after 
taking 100 pcs of 100 mg tablets containing phenytoin with the 
intention of committing suicide. The vital signsof the patient at the 
time of admission were:blood pressure (BP): 100/60 mmHg, 
pulse:93 pulse/min, saturated O2 : 100%, fever: 36.7°C, and 
respiratory rate: 22/min. The patient wasconfused and prone to 
sleeping, and all other system examinations were normal. Although 
the period of time that had elapsed from the intake of the 
druguntilthe administrationofemergency health procedures was not 
clear, according to the anamnesis taken from her relatives, it ranged 
from 30 and 60 minutes. The laboratory test results for the patient, 
were: pH: 7,37, pCO2: 43, pO2: 97, HCO2: 22, glucose:154, urea:8 
creatinine:0.62, Na: 135, K:3.68, Cl:103, albumin:4.1, total bilirubin: 
0.4, direct bilirubin: 0.17, AST:10, ALT:11, GGT:14, ALP:52, 
LDH:145, AMYLASE:23, LIPASE:7, Beta hCG<1.20 Hb:11.1, 
Htc:35.5, leucocyte:7.17, platelet:243000 Pt:12.5sn, INR:0.89, 
APTT:21.7, ethanol: <10.0 mg/dl, phenytoin: 124.6 ug/mL. 
Stomach lavage was applied to the patient via an orogastric 
catheter, and then 1mg/kg activated charcoal was given. The 
patient, who was registered withthe national poison information 
system, was taken to our emergency intensive care unit for follow-
up due to life threatening injury. After the initial dose of 1 mg/kg 
activated charcoal, additional doses of 0.5 mg/kg every 6 to 8 hours 
were administered to the patient for a total of 60 hours. Limitation 
of movement was prescribed for the patient, who had agitation and 
clouding of consciousness on the first day. Daily phenytoin dose 
follow-up was conducted (Table 1). The phenytoin dose that was 
124.6 ug/mL on the first day was 107.4 ug/mL on the second day, 
110.4 ug/mL on the third day,113.2 ug/mL on the fourth day, 98.6 
ug/mL on the fifth day, 69.0 ug/mL on the sixth day, and 66.5 
ug/mL on the seventh day.The patient's level of confusion was 
followed-up inthe intensive care unit for 3 days. She appeared to 
have recovered on the firstday, but her agitation regressed and her 
follow-up continued in the emergency department observation unit 
for 4 days. The patient, who developed no additional pathology and 
whose existing complaints regressed, was transferred in a good 
general condition and stable vital signs, to the psychiatry 






Antiepileptic drugs (AEDs) are a major treatment consideration for 
patients with epilepsy; therefore, the efficient control of seizures is 
the main concern when choosing the appropriate drug and dosage. 
A number of factors, including patient age and polypharmacy, 
increase the risk of side effects for AEDs [5]. Moreover, as has been 
reported in the literature, the results from this present study 
showed that there was no relationship between serum levels of 
AEDs and their side effects [6]. Phenytoin acts by inducing voltage-
dependent and use-dependent blockage of the sodium channels. 
Phenytoin is one of a handful of drugs for which the kinetics change 
from the first order,"in which the extent of metabolism is directly 
correlated with the amount of available drug", to saturation at 
therapeutic doses. Accordingly, at a plasma concentration of around 
15 ug per ml, a moderate increase in the drug dose can cause an 
unexpectedly large increasein the plasma concentration. A starting 
dose of 5 mg per kilogram of body weight increases the plasma 
concentrations; in most patients, the target range total is 20 ug per 
ml, but the concentrations are higher in some patients, resulting in 
neurotoxic effects [7]. In general, the dose can be increased by l00 
mg if the plasma drug concentration is 8 ug per ml or less, but no 
more than 50 mg should be added if the plasma drug concentration 
is higher than 8 ug per ml. Some patients can benefit from plasma 
concentrations above 25 ug per ml without sideeffects. Phenytoin 
can cause a range of dose-related and idiosyncratic adverse effects. 
Reversible cosmetic changes (gum hypertrophy, acne, hirsutism, 
and facial coarsening), can be troublesome even though they tend 
to be mild. Neurotoxic symptoms (drowsiness, dysarthria, tremors, 
ataxia, and cognitive difficulties) become increasingly likely when 
the plasma drug concentration exceeds 20 ug per ml [6]. Even if the 
serum drug level is high, in some cases the absence of a clinical 
picture, which is observed in the literature [8] (Table 2), can be 
explained by genetic disorders at the receptor level between the 
drug metabolism and its activity [9]. It has been acknowledged that, 
PGP, a MDR1 gene product, is also found on the apical faces of 
normal cells in the large and small bowel columnar epithelium, the 
brush border of the renal tubuli, the biliary canaliculi of the 
hepatocyte, the pancreatic ductuli, the glandular epithelial cells of 
the endometrium in pregnant women, and also in the capillary 
endothelial cells of the blood-brain and blood-testicle barriers; 
moreover, other than the MDR phenotype, PGP is involved in 
various physiologic processes and augments its expression with 
appropriate stimulus.PGP performs the MDR function not by 
membrane permeability regulation but by acting as an ATP-
dependent efflux pump from inside the cell to outside the cell [10]. 
Phosphorylation of PGP regulates the exocytosis mechanism of the 





While the cytochrome P-450 gene plays an active role in drug 
metabolism, the MDR1 gene playsan active role in the efficiency of 
the drug at the receptor level. Whether or not this results in an 
increase in the serum drug level, we think that the personalization 
of the drug level correlated with this gene mutation and the clinical 
findings are suitable after observing depletion of MDR1 and 
cytochrome P-450 genes in diseases requiring chronic drug use. In 
our case study, we considered that the absence of symptoms 
correlated with serum drug level could be caused by the deletions in 
the MDR1 gene or the cytochrome P450 gene.  
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Table 2: correlation of serum phenytoin level and clinical effects 
µg/ml (mg/L) Clinical Effects 
<10 Non effects 
10-20 Horizontal nistagmus 
20-30 Spontan nistagmus 
30-40 
Tremor,diplopia, vertical nystagmus,  
ataxia, hyperreflexia 
40-50 Lethargy, disorientation,  confusion, hyperactivity 
>50 Coma, seizures 
  
 
